Palisade Bio
PALI
9 hedge funds and large institutions have $485K invested in Palisade Bio in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
29% more funds holding
Funds holding: 7 → 9 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
8% less capital invested
Capital invested by funds: $527K → $485K (-$42K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$63K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$12K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$229K |
| 2 |
Renaissance Technologies
New York
|
-$63K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $147K | -$63K | -21 | -36% |
|
|
VF
2
Virtu Financial
New York
| $109K | +$63K | +21 | +350% |
|
|
3
HighTower Advisors
Chicago,
Illinois
| $88K | -$33K | -11 | -33% |
|
4
Bank of New York Mellon
New York
| $42K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $37K | +$12K | +4 | +80% |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $32K | +$24K | +8 | New |
|
|
7
Northern Trust
Chicago,
Illinois
| $16K | +$12K | +4 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $9K | +$6K | +2 | New |
|
9
BlackRock
New York
| $3K | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
SM
11
Sabby Management
Miami Beach,
Florida
| – | -$229K | -87 | Closed |
|
PALI Hedge Fund Activity: Q4 2020 in Review
9 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2020, worth a combined $485K — down 8% from $527K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PALI positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, adding an estimated $63K. The largest seller was Sabby Management, exiting entirely with an estimated $229K sold.
- 9 institutional investors held Palisade Bio (PALI) as of Q4 2020, up from 7 in Q3 2020.
- Funds reported $485K of Palisade Bio stock for Q4 2020, down 8% quarter-over-quarter.
- 3 funds opened new Palisade Bio positions in Q4 2020 and 1 closed out, a net change of +2 holders.
- The largest Palisade Bio buyer in Q4 2020 was Virtu Financial, an estimated $63K added.
- The largest Palisade Bio seller in Q4 2020 was Sabby Management, an estimated $229K sold.
Based on aggregated 13F filings for Q4 2020.